Koers TapImmune Inc. OTC Bulletin Board
Aandelen
TPIV
US8760334081
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 1,24 mln. 1,16 mln. | Omzet 2025 * | - | Marktkapitalisatie | 41,38 mln. 38,63 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -21 mln. -19,6 mln. | Nettowinst (verlies) 2025 * | -32 mln. -29,87 mln. | EV/omzet 2024 * | 33,3 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,83
x | K/w-verhouding 2025 * |
-3,49
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 0% |
Recentste transcriptie over TapImmune Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 44 | 17-10-18 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-11-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Norman Eansor
CHM | Chairman | 63 | 17-10-18 |
Steven Elms
BRD | Director/Board Member | 60 | 06-08-19 |
Katharine Knobil
BRD | Director/Board Member | 60 | 08-12-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,36% | 52,5 mld. | |
+36,73% | 39,31 mld. | |
-8,63% | 39,01 mld. | |
+25,46% | 28,2 mld. | |
-11,17% | 26,57 mld. | |
+11,44% | 26,2 mld. | |
+45,09% | 14,15 mld. | |
+32,93% | 12,62 mld. | |
-5,30% | 11,74 mld. |